Side-by-side comparison of AI visibility scores, market position, and capabilities
LinusBio is a precision medicine company using AI-powered exposome sequencing of hair samples to detect environmental and genetic disease risk factors; focuses on early autism detection; spun out of MIT; raised $12.5M in Series A funding.
LinusBio is a precision medicine and diagnostics company founded by Manish Arora and headquartered in New York, with roots in research at the Icahn School of Medicine at Mount Sinai and MIT. The company has developed a proprietary technology platform called exposome sequencing — a method of analyzing biological samples, primarily hair, to reconstruct a detailed timeline of environmental exposures and biological changes over months or years. This approach enables early detection of disease risk factors by reading both genetic and environmental signals simultaneously.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.